Connected microphysiological systems that model organ-organ interactions, ADME pharmacokinetics, and systemic toxicity for whole-body drug response prediction
Multi-organ-on-chip (MOC) systems connect multiple organ-on-chip devices through microfluidic channels, enabling the study of complex organ-organ interactions and systemic drug responses. Unlike isolated single-organ models, these platforms capture the interconnected nature of human physiology - how drugs move between organs, how metabolites from one organ affect another, and how systemic toxicity emerges from multi-organ dysfunction.
By linking organs like liver, gut, kidney, heart, lung, and brain in physiologically-relevant configurations, MOC systems create miniature representations of human body function. This enables researchers to study pharmacokinetics (how the body processes drugs) and pharmacodynamics (how drugs affect the body) with unprecedented accuracy before human clinical trials.
Emulate's connected liver-intestine-chip system identified drug-induced liver injury that was missed by single-organ models, correctly predicting clinical outcomes for drugs that had failed in trials due to unexpected hepatotoxicity.
Body-on-chip platform with interconnected organ modules and continuous circulatory flow
While multi-organ chips connect 2-4 organs for specific studies, body-on-chip (also called human-on-chip) aims to replicate comprehensive human physiology by connecting 10+ organs in physiologically-scaled ratios. This creates a miniature circulatory system where drugs flow through organs in the same sequence and timing as in the human body.
The goal is to create a "universal translator" that converts in-vitro results to in-vivo predictions with high accuracy. By maintaining proper organ-to-organ ratios, flow rates, and residence times, body-on-chip systems can predict human pharmacokinetics - including Cmax (peak concentration), half-life, AUC (area under the curve), and clearance rates.
Key principles of body-on-chip design include:
Multi-organ systems reveal organ-organ crosstalk that single-organ models cannot capture. These physiological axes are essential for understanding drug behavior and toxicity:
The most critical axis for oral drug development. The gut absorbs drugs, which flow directly to the liver via the portal vein for first-pass metabolism. This axis determines bioavailability and can convert prodrugs to active forms or generate toxic metabolites.
Bidirectional communication between intestinal microbiome and central nervous system. Affects drug absorption, mood disorders, neuroinflammation, and CNS drug delivery. Critical for understanding gut-derived metabolite effects on brain function.
Liver metabolizes drugs; kidney excretes metabolites. Dysfunction in either organ affects the other's drug handling. Critical for understanding drug clearance, accumulation, and nephrotoxicity from hepatic metabolites.
Liver metabolites can cause cardiotoxicity; cardiac output affects liver perfusion. Essential for identifying QT prolongation risk from hepatic metabolites and understanding drug-induced arrhythmias.
Inhaled drugs can undergo pulmonary first-pass metabolism before systemic distribution. Lung-liver connectivity important for inhaled therapeutics and understanding respiratory drug delivery.
Metabolic organs that control glucose homeostasis and lipid metabolism. Critical for diabetes and obesity drug development, understanding drug partitioning, and modeling metabolic disease states.
ADME (Absorption, Distribution, Metabolism, Excretion) describes how the body processes drugs. Multi-organ systems uniquely capture all four ADME phases in a single integrated platform, providing human-relevant pharmacokinetic data.
Drug uptake from administration site into systemic circulation
Drug movement from blood to tissues throughout body
Biotransformation of drugs into metabolites
Elimination of drugs and metabolites from body
By connecting absorption (gut/lung), metabolism (liver), and excretion (kidney) organs with distribution compartments, multi-organ chips generate human PK parameters:
Multi-organ chips generate concentration-time curves matching human PK profiles
Multi-organ systems excel at detecting systemic toxicity - adverse effects that emerge from organ-organ interactions or circulating metabolites. These toxicities are often missed by single-organ models but cause drug failures in clinical trials.
Types of systemic toxicity captured by multi-organ chips:
For example, a drug might be safe in liver-only tests but cause cardiotoxicity when liver-generated metabolites reach the heart - detectable only in connected liver-heart systems.
Human Emulation System connecting liver, intestine, lung, kidney chips with automated control
HUMIMIC platforms with up to 10 organs; multi-organ-chip pioneers from Germany
Multi-organ systems with integrated electrical and biosensor readouts for functional testing
PhysioMimix connecting liver, gut, lung for ADME and multi-organ toxicity studies
OrganoPlate high-throughput platform for multi-organ arrays and compound screening
ParVivo chips with perfused tubular structures for kidney-liver and multi-organ studies
Building physiologically-relevant body-on-chip systems requires solving complex engineering challenges:
Emulate's connected Liver-Chip and Intestine-Chip system was used to study drugs that had caused unexpected hepatotoxicity in clinical trials. The gut-liver axis model correctly identified the liver injury risk that animal models and single-organ liver tests had missed. The system detected that intestinal absorption and first-pass metabolism together generated toxic metabolites at clinically-relevant concentrations.
TissUse developed a 4-organ HUMIMIC chip connecting intestine, liver, kidney, and skin to model complete ADME for oral and topical drugs. The platform maintained organ function for 28 days, enabling chronic toxicity studies. Results showed 10x better correlation with human PK parameters than animal models, with accurate prediction of bioavailability and clearance rates.
Hesperos' connected heart-liver chip identified that a drug candidate's hepatic metabolite caused QT prolongation, while the parent drug showed no cardiac effects. The integrated electrical sensing detected arrhythmia risk only when both organs were connected - the metabolite generated by the liver reached the heart at concentrations causing action potential changes. This finding would have been missed by isolated cardiac safety testing.
Multi-organ-on-chip systems are gaining regulatory recognition as valid New Approach Methodologies (NAMs) for drug development:
While full regulatory qualification is ongoing, multi-organ chip data is increasingly supporting clinical trial design, dosing decisions, and safety assessments in regulatory submissions.
A multi-organ-on-chip (MOC) system connects multiple organ-on-chip devices through microfluidic channels, enabling the study of organ-organ interactions and systemic drug responses. These platforms link organs like liver, gut, kidney, heart, and brain to model whole-body physiology on a chip scale, capturing ADME processes and multi-organ toxicity that single-organ models miss.
Multi-organ-on-chip typically refers to systems connecting 2-4 organs for specific interaction studies (like gut-liver or heart-liver). Body-on-chip aims to replicate comprehensive human physiology by connecting 10+ organs in physiologically-scaled ratios, creating a miniature human-on-chip for complete systemic drug response modeling including circulation, metabolism, and elimination.
Many drug failures occur due to unexpected organ-organ interactions. For example, the gut-liver axis determines first-pass metabolism affecting bioavailability, while kidney-liver crosstalk impacts drug clearance. The gut-brain axis influences CNS drug effects, and heart-liver interactions can reveal cardiotoxicity from hepatic metabolites. Multi-organ systems capture these interactions that isolated organ models cannot detect.
ADME stands for Absorption (gut), Distribution (blood, tissues), Metabolism (liver), and Excretion (kidney). Each ADME process involves different organs working together. Multi-organ chips connect these organs fluidically to model complete drug pharmacokinetics - how a drug enters the body, spreads to tissues, gets metabolized, and is eliminated - providing human-relevant PK data before clinical trials.
Key challenges include: 1) Maintaining physiological organ size ratios while keeping the system small enough for practical use, 2) Balancing media flow rates to deliver nutrients without shear stress damage, 3) Creating a universal media that supports all cell types, 4) Achieving sufficient cell numbers for metabolic function while preventing oxygen/nutrient gradients, and 5) Integrating real-time sensing without disrupting the system.
Leading companies include: Emulate (Human Emulation System connecting multiple chips), TissUse (HUMIMIC platforms with up to 10 organs), Hesperos (multi-organ platforms with integrated biosensors), CN Bio (PhysioMimix connecting liver, gut, and lung), Mimetas (OrganoPlate for high-throughput multi-organ studies), and academic pioneers like the Wyss Institute and MIT's body-on-chip programs.
Yes, the FDA has accepted organ-on-chip and multi-organ data in IND applications. The FDA Modernization Act 2.0 (2022) and 3.0 (2024) explicitly recognize multi-organ systems as valid New Approach Methodologies. FDA and EMA are developing qualification frameworks for these platforms, and several companies have received positive feedback on using multi-organ data to support clinical trial design and safety assessments.
Experience interactive multi-organ-on-chip technology in our virtual lab
Body-on-Chip Sim PK Modeler Single-Organ Chips All Technologies